Close Menu
Business Voice NowBusiness Voice Now
    Facebook X (Twitter) Instagram
    Business Voice NowBusiness Voice Now
    Subscribe
    • Markets
      • IPO
      • Market News
    • Business
      • FMCG
      • Retail
      • Quick Commerce
      • Startups
    • Healthcare
    • Technology
    • Energy
    • Voices
      • Entrepreneur – CXO Stories
      • Corporate Office story
    • E Magazine
      • Year 2026
        • November 2026
        • October 2026
        • September 2026
        • August 2026
        • July 2026
    Business Voice NowBusiness Voice Now
    Home»National»Optimus Announces Interim Clinical Results from Phase III Clinical Trials of Molnupiravir Conducted in India
    National

    Optimus Announces Interim Clinical Results from Phase III Clinical Trials of Molnupiravir Conducted in India

    By July 21, 2021No Comments2 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Email
    Follow Us
    Google News Flipboard Threads
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Hyderabad (Telangana) [India], July 21: Optimus Pharma on Sunday submitted the interim result of Phase III Clinical Trials for orally administered Molnupiravir capsules on patients with Mild Covid-19 patients. With an acute shortage of antiviral drugs in the market against the SARS-CoV-2 infection, it is imperative that more drugs with potent antiviral activity against SARS-CoV-2 be introduced.

    In a statement, the MD and Chairman Dr. D Srinivasa Reddy had declared that Optimus pharma has internally developed the active pharmaceutical ingredient (API) and the formulations for the product and had obtained approval for conducting Phase 3 Clinical Trial.

    As per the clinical trial protocol approved, 1218 subjects with mild COVID-19 will be randomised in the study in a 1:1 ratio to Molnupiravir with the standard of care, or standard of care alone. The treatment duration is a maximum of 05 days and the total study duration will be a maximum of 28 days from randomisation.

    “Optimus is all geared to immediately begin manufacturing of Molnupiravir for COVID-19 patients in India. The interim results on 353 patients have shown promising results of Molnupiravir. The drug has been successful in reducing viral load effectively with RT-PCR negativity achieved 78.3 % in the test arm compared to 48.4% in the standard of care arm on Day 5. Day 10 and Day 14 of the treatment duration have also given excellent results wherein the remaining patients have successfully achieved RT-PCR negativity. The trial has also revealed clinical improvement in a significantly high proportion of patient’s health. The safety of the drug has also been established with no observed side effects, co-morbidity, or morbidity observed during and after the treatment duration,” Chairman & Managing Director – Dr. D Srinivasa Reddy said.

    Optimus has approached the Drugs Controller General of India (DCGI) to seek Emergency Use Authorization for Molnupiravir in India.

    Optimus Pharma is committed to serve the nation and fight back the pandemic to restore normalcy in the lives of people affected by COVID-19 at the earliest. With the cooperation of the government and our stakeholders, and a special thanks to the Subject Expert Committee of the CDSCO for their valuable contribution and their recommendations to the project, we hope to deliver the product in India by leveraging our solid distribution strength across the country.

    national
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    How Officebing Plans Workplaces Around Different Functions

    November 18, 2026

    Inspiring Infosys’ SellWell Platform to Highlight Technology-Driven E-commerce Solutions at Tech Expo Gujarat 2026

    November 18, 2026

    A Rs 15.53 Crore Residential Deal in Vile Parle West Sets New Benchmark

    November 17, 2026

    Comments are closed.

    Recent Post
    • Irfan Pathan and Adah Sharma Grace the Launch of Youth Cricket League’s YCLT10
    • From Military Service to Social Change: Ramesh Sangle Explores Nation-Building in BRIGADE
    • How Officebing Plans Workplaces Around Different Functions
    • Inspiring Infosys’ SellWell Platform to Highlight Technology-Driven E-commerce Solutions at Tech Expo Gujarat 2026
    • Manav’s ‘Bardic Voices: Where the Horizon Meets, the Magic Begins’ Explores Memory, Humanity, and the Search for Meaning
    • Glen Industries Limited Reports H1 FY27 Results
    • Spreading Bliss Foundation Supports Children in Orphanage
    • Mastertrust Launches mtAlgoZ to Enhance Digital Trading with Automated Strategy Building and Execution

    Type above and press Enter to search. Press Esc to cancel.